Posters

Initial clinical results of a new phakic toric intraocular lens

Poster Details

First Author: D.Yaşa TURKEY

Co Author(s):    B. Köse   A. Ağca                 

Abstract Details

Purpose:

To report early clinical experience with a new foldable, hydrophilic acrylic, single piece, injectable, Phakic Toric IOL

Setting:

Beyoglu Eye Training and Research Hospital, Istanbul, Turkey

Methods:

Medical records of patients who underwent posterior chamber phakic IOL (Eyecryl Phakic Toric, Biotech Vision Care, Ahmedabad, India) implantation were retrospectively reviewed. Manifest refraction, uncorrected (UDVA) and corrected (CDVA) distance visual acuities, central endothelial cell density (ECD), pIOL vault and pIOL rotation were evaluated over 6 months.

Results:

43 eyes of 23 patients were included. At the 6-month, the SE was within ±0.50 D of emmetropia in 30 (70%) eyes and within ±1.00 D of emmetropia in 39 (91%) eyes. The efficacy and safety indices were 1,25±0,38 and 1,41±0,34 respectively. Mean ECD was 2719 ± 296 cells/mm2 at the preoperative visit and 2779,42 ± 422 cells/mm2 at the 6-month visit (p>0.05). The mean value of absolute axis orientation error was 4,95±5,28⁰. Mean absolute change in axis orientation between visits was less than 3⁰ for all visit intervals. Ninety percent or more of lenses rotate 5⁰ or less between all visit intervals. None of the patients experienced a vision threatening complication and no patient required secondary IOL repositioning. No patient lost 2 or more lines of CDVA.

Conclusions:

The pIOL appear to effectively reduce subjective manifest astigmatism and provide good visual acuity. Its position was stable throughout the follow-up exceeding the ANSI standard for toric IOLs for lens stability.

Financial Disclosure:

None